Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | CBLB | Q13191 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044094 | 0.84 | ATAD2 (0.41) | FFAR2MEN1KMT2ALMNAHPGD | |
| SCHEMBL9928614 | 0.80 | ALDH1A1 (0.38) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL312511 | 0.78 | FABP4 (0.36) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL577680 | 0.77 | CYP3A4 (0.39) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL578067 | 0.77 | FFAR2 (0.38) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL1989340 | 0.76 | MEN1 (0.35) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL20993710 | 0.75 | CTSK (0.49) | CTSKFFAR2IRAK4PTGES | |
| SCHEMBL6840492 | 0.74 | HSD17B10 (0.43) | FFAR2KMT2ALMNAHPGDHTT | |
| Acetic Acid SCHEMBL15573175 | 0.72 | MEN1 (0.35) | CTSKFFAR2CBLBMEN1KMT2A | |
| SCHEMBL485822 | 0.72 | ALDH1A1 (0.44) | CTSKMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | JAK2, JAK1, JAK3 | CTSK 2584/4885FFAR2 3869/4885CBLB 342/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CTSK 2596/4885FFAR2 3798/4885CBLB 261/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CTSK 2584/4885FFAR2 3869/4885CBLB 342/4885 |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CTSK 2584/4885FFAR2 3869/4885CBLB 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.